Aberrant Expression of Napsin A in Breast Carcinoma With Apocrine Features

Int J Surg Pathol. 2016 Aug;24(5):377-81. doi: 10.1177/1066896916629781. Epub 2016 Feb 3.

Abstract

An incidental finding of napsin A-positive breast carcinoma with apocrine features during workup for metastatic cancer in an axillary lymph node led to our investigation of the incidence of napsin A expression in breast carcinomas, focusing on those with apocrine features. We included 97 cases of breast carcinomas and performed immunohistochemistry with napsin A, GATA-3, thyroid transcription factor-1, and GCDFP-15. There was a statistically significant difference between apocrine and nonapocrine cases with respect to polyclonal napsin A H-scores (P < .00152), monoclonal napsin A H-scores (P < .00631), GATA-3 H-scores (P < .00029), and GCDFP-15 H-scores (P < .00251). Of the 49 cases of apocrine carcinoma, monoclonal napsin A antibody was positive in 66.7% of cases, including in 7 (14.6%) that showed 3+ staining. The majority of nonapocrine cases were negative (62.5%) or weakly (1+) positive (29.2%), with none exhibiting 3+ strength. It is important for pathologists to be aware that breast carcinomas with apocrine features can express napsin A.

Keywords: apocrine; breast; napsin A.

MeSH terms

  • Aspartic Acid Endopeptidases / analysis
  • Aspartic Acid Endopeptidases / biosynthesis*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / pathology*
  • Carcinoma, Ductal, Breast / diagnosis
  • Carcinoma, Ductal, Breast / pathology*
  • Female
  • Humans
  • Immunohistochemistry

Substances

  • Biomarkers, Tumor
  • Aspartic Acid Endopeptidases
  • NAPSA protein, human